Introduction: The SCAN lung cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for the use of adjuvant systemic therapy for non-small cell lung cancer in Singapore.Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. Results: : Five international guidelines were evaluated—those developed by the National Comprehensive Cancer Network (2014), European Society of Medical Oncology (2014), National Institute of Clinical Excellence (2012), Scottish Intercollegiate Guidelines Network (2014), and the Cancer Care Council Australia (2012). Recommendations on the selection of patients, chemotherapy regimen, treatment for stage I disease, treatment for positive margins and treatment options for pN2 disease with negative margins were produced. Conclusion: : These adapted guidelines form the SCAN Guidelines 2015 for adjuvant systemic therapy of non-small cell lung cancer.
In Singapore and also worldwide, lung cancer is one of the most common cancers and is also a leading cause of cancer-related deaths. In Singapore, there were 6558 cases of newly diagnosed lung cancer and 5628 deaths from 2009 to 2013. Lung cancer is the leading cause of cancer mortality among males and second highest among females in Singapore. Approximately 15% of patients with non-small cell lung cancer (NSCLC) present in the early stage (stage I-II) where surgery is the mainstay of curative treatment. Long-term survival however remains poor with distant failure being a major cause of relapse.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.